Heidelberg Pharma

Heidelberg Pharma and Huadong Medicine have signed an expanded cooperation agreement to jointly research and advance early development of new antibody–drug conjugates (ADCs). The collaboration covers up to six target molecules and combines Heidelberg’s ATAC® technology with Huadong’s R&D capabilities and new toxin payloads. The goal is next‑generation ADCs, including bispecific and multispecific formats as well as dual‑payload candidates, with ownership of development candidates to be allocated according to each party’s contributions. » More on de.investing.com

Heidelberg Pharma has established the recommended Phase II dose (RP2D) for the ADC candidate HDP-101 (pamlectabart tismanitin), thereby completing the Phase I portion of the ongoing study. The Safety Review Committee recommended the step after reviewing safety, tolerability and pharmacokinetic data; pamlectabart was well tolerated across all doses and a maximum tolerated dose was not reached. Promising efficacy signals were observed in the higher cohorts, so recruitment into the Phase IIa part with up to 30 patients is expected to begin in the coming weeks. Detailed safety and efficacy data and the selection of the RP2D will be presented at a scientific conference. » More on de.investing.com

Heidelberg Pharma is reducing its workforce by about 75% and concentrating resources on its lead ADC program HDP-101 after a regulatory setback at Telix that delayed expected milestone payments. For 2025 the company reported a net loss of €42.3 million, negative equity and reduced cash; through a revised financing it received an advance payment of $20 million and extends its runway to mid-2027. The HDP-101 study shows encouraging response rates in higher dose cohorts, dose escalation continues and a recommended phase‑II dose is expected in H1 2026. HDP-102 has been suspended and is available for partnerships; management expects higher revenues for 2026 (€11–15 million) and substantially lower operating expenses. » More on de.investing.com